Prescription medicine
Torsemide Brand names: Soaanz; first approved as Demadex
Torsemide (Demadex) is a prescription medicine with an FDA approval on record since 1993. FDA's NDC Directory lists it from 20 generic labelers, and pharmacies paid $0.0636 per torsemide 20 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the torsemide FDA label on DailyMed (effective May 8, 2024, Aurobindo Pharma Limited); the NDA 20136 record on Drugs@FDA; every torsemide label on DailyMed.
Highlights of the record
FDA label of May 8, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTorsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease.
Forms and strengths
- 5 mg
- 10 mg
- 20 mg
- 40 mg
- 100 mg
Tablet; film-coated tablet.
On the market
- Earliest approval on file
- August 23, 1993 Demadex, Pharmobedient; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 12 first May 14, 2002; 6 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 21 of which 20 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- October 6, 2033 Soaanz tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.0636 per tablet Torsemide 20 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 2 since 2013 0 Class I among all firms' recalls; latest December 14, 2016; 2 more by firms not listed as its makers
- FAERS reports
- 32,925 through July 30, 2026
What is torsemide used for?
From the label: indications and usageTorsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. […]
Conditions named in the indications of torsemide's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Loop Diuretic.
Source: FDA drug label (Torsemide), Aurobindo Pharma Limited, effective May 8, 2024 (SPL set 55e88727-864e-4313-860c-31a6ca45168f), via openFDA; the full label on DailyMed
Is there a generic for torsemide (Demadex)?
The FDA approved the first generic torsemide on May 14, 2002. 12 generic applications are approved; 6 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists torsemide from 20 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Demadex tablets; a patent listed only for Soaanz tablets runs to October 6, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1993 earliest approval on file
- 2002 first generic approved
- 2033 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for torsemide (Demadex)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0636 per Torsemide 20 mg tablet, down 12% from $0.072 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Torsemide 20 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Torsemide 10 mg tablet | Generic | $0.0659 per tablet | $1.98 | -12% |
| Torsemide 100 mg tablet | Generic | $0.174 per tablet | $5.22 | -17% |
| Torsemide 20 mg tablet | Generic | $0.0636 per tablet | $1.91 | -12% |
| Torsemide 5 mg tablet | Generic | $0.0573 per tablet | $1.72 | -15% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has torsemide been recalled?
The FDA's Enforcement Report lists 4 recalls naming torsemide since 2013: 0 Class I (the most serious), 4 Class II, 0 Class III; 0 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of torsemide and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 14, 2016 | Class II | Apotex Corp. | CGMP Deviations |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup; TORSEMIDE Tablet, 10 mg may be potentially mislabeled as MEXILETINE HCL, Capsule, 200 mg, NDC 00093874001, Pedigree: AD25264_7, EXP … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup; TORSEMIDE, Tablet, 10 mg may be potentially mislabeled as PYRIDOXINE HCL, Tablet, 50 mg, NDC 00536440801, Pedigree: AD30197_22, EXP … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the torsemide label say about other medicines?
The torsemide label names 13 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amiodarone | drug interactions | Concomitant use of CYP2C9 inhibitors (e.g., amiodarone, fluconazole, miconazole, oxandrolone) can decrease torsemide clearance and increase torsemide plasma concentrations. |
| Celecoxib | drug interactions | Because of its inhibition of CYP2C9 metabolism, torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates, such as celecoxib, or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. Monitor patients and adjust dosages if necessary. |
| Cholestyramine | drug interactions | Concomitant use of torsemide and cholestyramine has not been studied in humans but, in a study in animals, coadministration of cholestyramine decreased the absorption of orally administered torsemide. |
| Cisplatin | warnings and precautions | Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). Monitor volume status and renal function periodically. |
| Ethacrynic acid | drug interactions | Loop diuretics increase the ototoxic potential of other ototoxic drugs, including aminoglycoside antibiotics and ethacrynic acid. |
| Fluconazole | drug interactions | Concomitant use of CYP2C9 inhibitors (e.g., amiodarone, fluconazole, miconazole, oxandrolone) can decrease torsemide clearance and increase torsemide plasma concentrations. |
| Indomethacin | drug interactions | Partial inhibition of the natriuretic effect of torsemide by concomitant administration of indomethacin has been demonstrated for torsemide under conditions of dietary sodium restriction (50 mEq/day) but not in the presence of normal sodium intake (150 mEq/day). |
| Lithium | drug interactions | Risk of lithium toxicity ( 7.5 ) Renin-angiotensin inhibitors: Increased risk of hypotension and renal impairment. ( 7.7 ) Radiocontrast agents: |
| Miconazole | drug interactions | Concomitant use of CYP2C9 inhibitors (e.g., amiodarone, fluconazole, miconazole, oxandrolone) can decrease torsemide clearance and increase torsemide plasma concentrations. |
| Phenytoin | drug interactions | Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. |
| Probenecid | drug interactions | Coadministration of organic anion drugs (e.g., probenecid) that undergo significant renal tubular secretion have the potential to reduce secretion of torsemide into the proximal tubule and thereby decreases the diuretic activity of torsemide. Monitor diuretic effect and blood pressure during coadministration. |
| Rifampin | drug interactions | Concomitant use of CYP2C9 inducers (e.g., rifampin) increase torsemide clearance and decrease plasma torsemide concentrations. |
| Warfarin | drug interactions | Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. |
Source: FDA drug label (Torsemide), Aurobindo Pharma Limited, effective May 8, 2024 (SPL set 55e88727-864e-4313-860c-31a6ca45168f), via openFDA; the full label on DailyMed
What do FAERS reports show for torsemide?
The FDA Adverse Event Reporting System holds 32,925 reports that list torsemide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 4,435 are coded as a death and 17,727 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as torsemide?
81 other medicines are given the same way (oral) and in the same FDA class as torsemide or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Furosemide | High blood pressure, Heart failure | 33 labelers | $0.026 per tablet 20 mg tablet | In shortage |
| Bumetanide | Heart failure | 24 labelers | $0.108 per tablet 1 mg tablet | Resolved |
| Ethacrynic acid | Heart failure | 8 labelers | $0.807 per tablet 25 mg tablet | No current entry |
| Metoprolol | High blood pressure, Heart failure | 64 labelers | $0.085 per tablet 100 mg tablet | A presentation being discontinued |
| Diltiazem | High blood pressure | 42 labelers | $0.144 per capsule 24h ER(cd) 120 mg capsule | A presentation being discontinued |
| Lisinopril | High blood pressure, Heart failure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Propranolol | High blood pressure | 38 labelers | $0.0493 per tablet 20 mg tablet | In shortage |
| Carvedilol | High blood pressure, Heart failure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does torsemide compare with medicines for the same use?
6 side-by-side pages set torsemide beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to torsemide
- 81 medicines for the same use
- Other loop diuretics
- the pharmacologic class, with prices and generics
- Torsemide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other